JP2018522592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522592A5 JP2018522592A5 JP2018524548A JP2018524548A JP2018522592A5 JP 2018522592 A5 JP2018522592 A5 JP 2018522592A5 JP 2018524548 A JP2018524548 A JP 2018524548A JP 2018524548 A JP2018524548 A JP 2018524548A JP 2018522592 A5 JP2018522592 A5 JP 2018522592A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cell line
- human
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 8
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 8
- 108700012411 TNFSF10 Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 6
- 108091008042 inhibitory receptors Proteins 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 201000009295 smoldering myeloma Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102000006471 Fucosyltransferases Human genes 0.000 claims 2
- 108010019236 Fucosyltransferases Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102000003838 Sialyltransferases Human genes 0.000 claims 2
- 108090000141 Sialyltransferases Proteins 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 1
- 108091008005 TRAIL–DR complexes Proteins 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 102000016887 Tumor Necrosis Factor Decoy Receptors Human genes 0.000 claims 1
- 108010053560 Tumor Necrosis Factor Decoy Receptors Proteins 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000004077 genetic alteration Effects 0.000 claims 1
- 231100000118 genetic alteration Toxicity 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112020A JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178899.9 | 2015-07-29 | ||
| EP15178899 | 2015-07-29 | ||
| GBGB1603655.0A GB201603655D0 (en) | 2016-03-02 | 2016-03-02 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| GB1603655.0 | 2016-03-02 | ||
| GB201605457 | 2016-03-31 | ||
| GB1605457.9 | 2016-03-31 | ||
| GB1610164.4 | 2016-06-10 | ||
| GBGB1610164.4A GB201610164D0 (en) | 2016-06-10 | 2016-06-10 | Modified natural killer cells and natural killer cell lines having increased cytoxicity |
| PCT/EP2016/068001 WO2017017184A1 (en) | 2015-07-29 | 2016-07-28 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112020A Division JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A Division JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522592A JP2018522592A (ja) | 2018-08-16 |
| JP2018522592A5 true JP2018522592A5 (enExample) | 2019-12-19 |
| JP6974681B2 JP6974681B2 (ja) | 2021-12-01 |
Family
ID=56683913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524548A Active JP6974681B2 (ja) | 2015-07-29 | 2016-07-28 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112020A Active JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A Pending JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112020A Active JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A Pending JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10034925B2 (enExample) |
| EP (6) | EP3434762B1 (enExample) |
| JP (3) | JP6974681B2 (enExample) |
| KR (1) | KR20180028530A (enExample) |
| CN (3) | CN108026512B (enExample) |
| AU (2) | AU2016300128B2 (enExample) |
| BR (1) | BR112018001660A2 (enExample) |
| CA (2) | CA2993796C (enExample) |
| DK (3) | DK3421590T3 (enExample) |
| ES (5) | ES2939084T3 (enExample) |
| HK (1) | HK1252582B (enExample) |
| MX (2) | MX380813B (enExample) |
| WO (1) | WO2017017184A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| ES2939084T3 (es) * | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| DK3581190T3 (da) | 2016-12-09 | 2021-06-07 | Onk Therapeutics Ltd | Manipulerede naturlige dræberceller og anvendelser deraf |
| US20200123503A1 (en) * | 2017-01-06 | 2020-04-23 | Nantkwest, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| WO2018148462A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| DE102017002645A1 (de) | 2017-03-17 | 2018-09-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen |
| WO2019016360A1 (en) * | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| CA3069557A1 (en) | 2017-07-21 | 2019-01-24 | Cellectis | Engineered immune cells resistant to tumor microoenvironment |
| US20200392458A1 (en) * | 2017-11-24 | 2020-12-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| EP3796924A4 (en) * | 2018-05-16 | 2022-01-12 | Research Institute at Nationwide Children's Hospital | PRODUCTION OF INACTIVATED PRIMARY AND EXTENDED HUMAN NK CELLS USING CAS9 RIBONUCLEOPROTEINS |
| WO2019232631A1 (en) * | 2018-06-06 | 2019-12-12 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for myeloid-derived suppressor cell enrichment |
| CN108743595B (zh) * | 2018-06-08 | 2020-11-27 | 厦门诺康得生物科技有限公司 | 一种nk细胞免疫检查点抑制剂及其制备方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| US20220143084A1 (en) * | 2019-02-15 | 2022-05-12 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| CN109908155A (zh) * | 2019-03-11 | 2019-06-21 | 上海中医药大学 | 丹参酮ⅱa的药物用途 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| KR20210142665A (ko) | 2019-03-21 | 2021-11-25 | 오엔케이 테라퓨틱스 리미티드 | 세포 사멸에 대한 증가된 내성을 갖는 변형된 면역 효과기 세포 |
| RU2731293C1 (ru) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
| CN115103910A (zh) | 2019-10-03 | 2022-09-23 | 工匠开发实验室公司 | 具有工程化的双引导核酸的crispr系统 |
| CN111849896B (zh) * | 2020-07-31 | 2022-07-01 | 广东昭泰体内生物医药科技有限公司 | 一种car-nk细胞培养基及其应用 |
| JP2023553419A (ja) | 2020-12-03 | 2023-12-21 | センチュリー セラピューティクス，インコーポレイテッド | 遺伝子操作細胞およびその使用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022182801A1 (en) | 2021-02-25 | 2022-09-01 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| WO2022256448A2 (en) | 2021-06-01 | 2022-12-08 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| JP2024522756A (ja) | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| WO2022266538A2 (en) | 2021-06-18 | 2022-12-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| CN114544971B (zh) * | 2022-02-22 | 2024-08-30 | 广东省科学院动物研究所 | 一种功能蛋白活性的检测方法 |
| EP4486881A1 (en) | 2022-03-01 | 2025-01-08 | Celyntra Therapeutics SA | Composition and methods for transgene insertion |
| CN114796483B (zh) * | 2022-06-28 | 2022-11-08 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| CN120091827A (zh) | 2022-11-10 | 2025-06-03 | 昂克医疗有限公司 | 使用免疫调节药物的联合疗法 |
| CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002216763B2 (en) | 2000-06-30 | 2007-03-01 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
| CA2388441A1 (en) | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
| WO2006004518A1 (en) * | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| DE602005016683D1 (de) * | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| EP1621550A1 (en) * | 2004-07-29 | 2006-02-01 | Dompé S.P.A. | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| GB0724532D0 (en) * | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| WO2012011113A2 (en) | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
| CN102908612A (zh) * | 2011-08-02 | 2013-02-06 | 北京诺赛基因组研究中心有限公司 | TRAIL截短型变异体活化NF-κB和在炎症反应中的应用 |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| AU2014223344A1 (en) * | 2013-02-27 | 2015-10-01 | Massachusetts Institute Of Technology | T cell balance gene expression, compositions of matters and methods of use thereof |
| EP3026292B1 (en) | 2013-07-25 | 2019-11-27 | Bridgestone Corporation | Vibration prevention device |
| SI3036258T1 (sl) * | 2013-08-22 | 2023-11-30 | The Council Of The Queensland Institute Of Medical Research | Modulacija imunoreceptorjev za zdravljenje raka in virusnih infekcij |
| WO2015057852A1 (en) * | 2013-10-15 | 2015-04-23 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4406610A3 (en) | 2014-04-07 | 2024-10-30 | Novartis AG | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| KR20250102123A (ko) | 2014-04-18 | 2025-07-04 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
| JP6839074B2 (ja) * | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| CN107847524A (zh) | 2015-03-27 | 2018-03-27 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| SG10201912978PA (en) * | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| ES2939084T3 (es) * | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US20200392458A1 (en) * | 2017-11-24 | 2020-12-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
-
2016
- 2016-07-28 ES ES21152473T patent/ES2939084T3/es active Active
- 2016-07-28 DK DK18187137.7T patent/DK3421590T3/da active
- 2016-07-28 ES ES20213303T patent/ES2970269T3/es active Active
- 2016-07-28 EP EP18194107.1A patent/EP3434762B1/en active Active
- 2016-07-28 CN CN201680049392.8A patent/CN108026512B/zh active Active
- 2016-07-28 CN CN202211000656.4A patent/CN116064401A/zh active Pending
- 2016-07-28 EP EP21152246.1A patent/EP3878951A1/en not_active Withdrawn
- 2016-07-28 ES ES18194107T patent/ES2876938T3/es active Active
- 2016-07-28 EP EP18187137.7A patent/EP3421590B1/en active Active
- 2016-07-28 ES ES18187137T patent/ES2890859T3/es active Active
- 2016-07-28 WO PCT/EP2016/068001 patent/WO2017017184A1/en not_active Ceased
- 2016-07-28 DK DK18194107.1T patent/DK3434762T3/da active
- 2016-07-28 MX MX2018001074A patent/MX380813B/es unknown
- 2016-07-28 CA CA2993796A patent/CA2993796C/en active Active
- 2016-07-28 CN CN202210987123.3A patent/CN116064400B/zh active Active
- 2016-07-28 BR BR112018001660-8A patent/BR112018001660A2/pt not_active Application Discontinuation
- 2016-07-28 EP EP21152473.1A patent/EP3828266B1/en active Active
- 2016-07-28 AU AU2016300128A patent/AU2016300128B2/en active Active
- 2016-07-28 EP EP20213303.9A patent/EP3971284B1/en active Active
- 2016-07-28 HK HK18111896.2A patent/HK1252582B/en unknown
- 2016-07-28 EP EP16750677.3A patent/EP3317401B1/en active Active
- 2016-07-28 KR KR1020187005673A patent/KR20180028530A/ko not_active Ceased
- 2016-07-28 DK DK16750677.3T patent/DK3317401T3/da active
- 2016-07-28 CA CA3156128A patent/CA3156128A1/en active Pending
- 2016-07-28 JP JP2018524548A patent/JP6974681B2/ja active Active
- 2016-07-28 ES ES16750677T patent/ES2701338T3/es active Active
-
2017
- 2017-01-12 US US15/405,163 patent/US10034925B2/en active Active
-
2018
- 2018-01-24 MX MX2020010014A patent/MX2020010014A/es unknown
- 2018-07-11 US US16/032,626 patent/US10960064B2/en active Active
-
2020
- 2020-11-30 US US17/107,696 patent/US20210138051A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112020A patent/JP7359346B2/ja active Active
- 2021-07-06 JP JP2021112019A patent/JP2021178824A/ja active Pending
-
2022
- 2022-05-18 AU AU2022203339A patent/AU2022203339A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522592A5 (enExample) | ||
| De Sousa Linhares et al. | Not all immune checkpoints are created equal | |
| Khan et al. | NK cell-based immune checkpoint inhibition | |
| Gogishvili et al. | SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes | |
| Stecher et al. | PD-1 blockade promotes emerging checkpoint inhibitors in enhancing T cell responses to allogeneic dendritic cells | |
| Hahn et al. | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 | |
| Zaghi et al. | Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy | |
| Beldi-Ferchiou et al. | Control of NK cell activation by immune checkpoint molecules | |
| MX2024002657A (es) | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. | |
| Cifaldi et al. | DNAM-1 activating receptor and its ligands: how do viruses affect the NK cell-mediated immune surveillance during the various phases of infection? | |
| Köhler et al. | The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation | |
| Sarkar et al. | Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A | |
| Littwitz et al. | Distinct roles of NK cells in viral immunity during different phases of acute Friend retrovirus infection | |
| Windheim et al. | A unique secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates leukocyte functions | |
| Kwon et al. | Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| Morales-Kastresana et al. | Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb | |
| Corgnac et al. | CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses | |
| Giuliani et al. | Novel targets for the treatment of relapsing multiple myeloma | |
| Konnai et al. | Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus | |
| Parsons et al. | Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells | |
| Newman et al. | Frontline science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8+ T cells | |
| Zhang et al. | Anti-West Nile virus activity of in vitro expanded human primary natural killer cells | |
| Meazza et al. | XLP 1 inhibitory effect by 2 B 4 does not affect DNAM‐1 and NKG 2 D activating pathways in NK cells | |
| Peng et al. | A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy |